European Companies Search Engine

Quick Search Power Search
Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

Expres2ION Biotechnologies ApS, Hørsholm, Denmark

Watch

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Dossier

The dossier is a printable PDF file, summarizing information and publications for this company. The creation of dossiers is included in your subscription. After the creation of the dossier is completed, it will be sent to your email address .

Add to dossier (if available):

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Name

Expres2ION Biotechnologies ApS

Register

Cvrcom
CVR 32770487

Address

Agern Alle 1, 2970 Hørsholm, Denmark
Rungsted Kyst, Denmark

Corporate purpose

The company's purpose is to conduct business in biotechnology

Additional info

72.11
Research and experimental development on biotechnology

Financials

Earnings Employees

Earnings

For this company, Earnings numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

Employees

For this company, Employees numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

History

Legal Representatives

Marketing & Tech

Network

Loading network

JOBS AT NORTH DATA

  • Director, Engineering
  • Modern Java Developer

Publications

28 Jun 2023
Annual report for the year ending 31/12/2022
28 Jun 2023
Company statute
22 Nov 2022 in Sat
State Aid (9,644,088 DKK): Grand Solutions (Public - Private Collaboration, Research and Development (Large projects))
6 Oct 2022
Persons
6 Oct 2022
Member of the Executive Board: Allan Rosetzsky
4 Jul 2022
Annual report for the year ending 31/12/2021
4 Jun 2021
Persons
3 Jun 2021
Annual report for the year ending 31/12/2020
2 Jun 2021
Member of the Executive Board: Karin Garre
2 Jun 2021
Member of the Executive Board: Sara Sande
4 Jun 2020
Annual report for the year ending 31/12/2019
4 Jun 2020
Auditor: Ernst & Young Partnership P/S
3 Jun 2020
Auditor: Beierholm · Proxy · Company statute
Year 2020 in Fts
5 EU fundings (total €1,471,224): 874653 - Indigo - Effective and Affordable FLU Vaccines for the World …
1 Apr 2020 in Hor
EU funding (€160,883): Prevention of SARS-CoV-2 infection through development and clinical testing of a novel Virus Like Particle (VLP) vaccine
12 Feb 2020 in Hor
EU funding (€610,338): Effective and Affordable Flu Vaccines for the World
10 Jan 2020
Patent: Glyco-Engineered Immunization Antigens
10 Jan 2020
Patent: Production of Protein with Humanized N-Glycosylation in Insect Cells
23 Dec 2019
Director: Steen Søren Klysner
20 Dec 2019
Persons
20 Dec 2019
Persons
11 Jun 2019
Annual report for the year ending 31/12/2018
15 Jun 2018
Persons
14 Jun 2018
Annual report for the year ending 31/12/2017
13 Jun 2018
Member of the Executive Board: Jakob Ole Knudsen
23 Feb 2018
Patent: A Malaria Vaccine and Methods for Producing Same
22 Dec 2017
Patent: New Flavivirus Vaccine
22 Jun 2017 via AdaptVac ApS
AdaptVac ApS
7 Jun 2017
Annual report for the year ending 31/12/2016
Year 2017 in Fts
4 EU fundings (total €45,826): 733273 - Optimalvax - Optimizing a Deployable High Efficacy Malaria Vaccine …
22 Dec 2016
Persons
20 Dec 2016
Capital: 530,835 DKK · Company statute
15 Dec 2016 in Hor
EU funding (€25,000): Development of Effective Vaccines against Multiple Lifecycle Stages of Plasmodium vivax malaria
15 Dec 2016 in Hor
EU funding (€445,056): Optimizing a deployable high efficacy malaria vaccine
1 Dec 2016
Member of the Executive Board: Charlotte Dyring
2 Jun 2016
Director: Charlotte Dyring
27 May 2016
Annual report for the year ending 31/12/2015
24 May 2016
Director: Charlotte Dyring
13 Apr 2016
Director: Steen Søren Klysner
14 Dec 2015
Company statute
27 Nov 2015
Persons
26 Nov 2015
Member of the Executive Board: Jesper Roested
27 May 2015
Patent: Improved Protein Expression System
22 May 2015
Annual report for the year ending 31/12/2014
20 Oct 2014
Member of the Executive Board: Alexander R. Duncan
2 Jun 2014
Annual report for the year ending 31/12/2013
22 Nov 2013
No longer Member of the Executive Board (1)
29 May 2013
Annual report for the year ending 31/12/2012
22 May 2013
Patent
1 Mar 2013 in Fts
EU funding (€990,905): Placmalvac
20 Dec 2012
Company statute
5 Jun 2012
Annual report for the year ending 31/12/2011
25 May 2012
Capital: 520,835 DKK · Company statute
26 Aug 2011
Capital: 453,126 DKK · Company statute
4 Aug 2011
Address
12 Jul 2011
Member of the Executive Board: Jesper Roested
6 Jun 2011
Annual report for the year ending 31/12/2010
10 Feb 2011
Auditor: Beierholm, Strandvejen 44 Danmark ApS
24 Nov 2010
Proxy
24 Sept 2010
Member of the Executive Board: Direktør Rosetzsky · No longer Member of the Executive Board (1) · Capital: 385,417 DKK · Company statute
16 Sept 2010
Member of the Executive Board (1)
12 Aug 2010
Proxy · Company statute
6 Jul 2010
Capital: 250,000 DKK · Company statute
4 Mar 2010
Address · Company statute
18 Feb 2010
Member of the Executive Board: Martin Roland Jensen · Director: Charlotte Dyring, Peter A. Stakemann · Auditor: Strandvejen 44 Danmark ApS · Address · Proxy · Company statute
18 Feb 2010
CEO: Martin Roland Jensen
12 Feb 2010
Reg­is­tra­tion · Director: Peter A. Stakemann · Founder: ApS Kbus 38 nr.3117 · Capital: 125,000 DKK · Proxy

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Creative Commons License The visualizations for "Expres2ION Biotechnologies ApS, Hørsholm, Denmark" are provided by North Data and may be reused under the terms of the Creative Commons CC-BY license.

Printing is only available to North Data premium service subscribers.
Close